Cross-Linked HA Did Not Outperform Saline
Two single-injection cross-linked hyaluronic acid formulations showed no statistically significant advantage over saline for pain or functional outcomes through 24 weeks.
By
Andrea Surnit
July 10, 2026
Clinical Scorecard: Cross-Linked HA Did Not Outperform Saline
At a Glance
Category Detail
Condition Knee Osteoarthritis Key Mechanisms Intra-articular injections of hyaluronic acid and saline Target Population Patients with symptomatic knee osteoarthritis unresponsive to conservative treatment Care Setting Randomized trial in a clinical research setting
Key Highlights
No significant differences in pain or functional outcomes between Hyruan ONE, hylan G-F 20, and saline. 276 patients participated in a double-blind, placebo-controlled trial. Pain scores decreased from baseline in all groups, but no between-group differences were found. 17% of Hyruan ONE, 21% of hylan G-F 20, and 25% of saline patients required rescue corticosteroids. Guideline-Based Recommendations
Diagnosis
Patients should be diagnosed with primary symptomatic knee osteoarthritis. Management
Intra-articular injections of hyaluronic acid and saline are options for management. Monitoring & Follow-up
Monitor pain and functional outcomes over time. Risks
Potential for inadequate symptom relief and need for rescue corticosteroids. Patient & Prescribing Data
Patients with symptomatic knee osteoarthritis who have not responded to at least 3 months of conservative treatment.
No superior efficacy of hyaluronic acid formulations over saline was observed.
Clinical Best Practices
Related Resources & Content
